Research
DMAE (Dimethylaminoethanol)
20 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Efficacy of dimethylaminoethanol (DMAE) containing vitamin-mineral drug combination on EEG patterns in the presence of different emotional states.
RCT of 80 subjects with threshold emotional disturbance testing a vitamin-mineral drug combination containing DMAE. After 6 and 12 weeks, the active group showed significant decreases in theta and alpha1 power in sensomotoric areas, associated with increased vigilance and attention. Mood scores improved, indicating better wellbeing.
Split face study on the cutaneous tensile effect of 2-dimethylaminoethanol (deanol) gel.
A split face randomized double-blind study compared the effect of a gel containing 3% DMAE with a formulation without DMAE. The DMAE formulation increased skin firmness, as indicated by increased shear wave velocity.
Source density analysis of functional topographical EEG: monitoring of cognitive drug action.
Double-blind, placebo-controlled study with 60 elderly volunteers assessing the effects of a drug containing DMAE, vitamins, and minerals on EEG changes during mental exercise. The treatment group showed decreases in theta power during rest and increases in absolute theta power during mental demand, indicating improved mental clarity.
The effects of deanol on cognitive performance and electrophysiology in elderly humans.
RCT of deanol (900 mg/day for 21 days) in elderly humans showed no effect on learning, reaction time, or continuous serial decoding of digits. Enhanced amplitude in evoked potentials was observed, but no changes in EEG spectrum. Deanol appears ineffective for cognitive function improvement in the elderly.
Ineffectiveness of deanol in tardive dyskinesia: a placebo controlled study.
Double-blind placebo-controlled study of deanol acetamidobenzoate in chronic schizophrenic patients with tardive dyskinesia. Deanol failed to alleviate dyskinetic movements and tended to increase schizophrenic symptoms, possibly due to interference with central cholinergic function.
Deanol and methylphenidate in minimal brain dysfunction.
Double-blind RCT involving 74 children with learning and behavior disorders, comparing deanol, methylphenidate, and placebo over 3 months. Both deanol and methylphenidate showed significant improvement on various tests, with deanol appearing to improve performance in children with learning and behavior disorders.
Double blind controlled trial of deanol in tardive dyskinesia.
Double-blind controlled trial with 33 psychiatric hospital subjects with tardive dyskinesia, divided into placebo, 1 g deanol, or 2 g deanol per day groups. After 30 days, the 2 g deanol group showed a significant reduction in movement ratings, with six subjects showing substantial reduction.
Double-blind trial of 2-dimethylaminoethanol in Alzheimer's disease.
A double-blind, placebo-controlled trial of 2-dimethylaminoethanol in 27 patients with Alzheimer's disease. Six patients in the drug group were withdrawn due to side effects, and no significant benefit was observed from the treatment.
Deanol, lithium and placebo in the treatment of tardive dyskinesia. A double-blind crossover study.
A double-blind crossover study on 29 chronic schizophrenic patients with tardive dyskinesia tested the effects of deanol and lithium carbonate. Patients received deanol, lithium carbonate, or placebo in addition to neuroleptics over 8-week periods with a 4-week wash-out in between. No statistically significant improvement in tardive dyskinesia was observed.
Double-blind evaluation of deanol in tardive dyskinesia.
Double-blind, placebo-controlled crossover trial of deanol acetamidobenzoate (2.0 g/day) in 14 patients with tardive dyskinesia. Both deanol and placebo improved patients' conditions significantly from baseline, with no distinction between treatments.
Deanol and physostigmine in the treatment of L-dopa-induced dyskinesias.
Double-blind, crossover RCT of deanol versus placebo in 10 parkinsonian patients with levodopa-induced dyskinesias. Deanol and placebo did not differ significantly in their effects on dyskinesias, suggesting the effects of deanol may be attributable to a placebo effect.
2-dimethylaminoethanol (Deanol) in Huntington's chorea.
A double-blind crossover trial with deanol in nine patients with Huntington's chorea found it to be ineffective in altering hyperkinesia.
Deanol in the treatment of tardive dyskinesia.
Double-blind, crossover RCT with 10 chronic psychotic patients with tardive dyskinesia, comparing deanol to placebo over 8 weeks. Improvement was observed in all patients during the first treatment phase, regardless of whether they received deanol or placebo. Deanol may have contributed to the decline in symptoms, but its effect was not dramatic.
Pharmacological characterization of tardive dyskinesia.
Six patients with tardive dyskinesia were evaluated with single challenge doses of various dopaminergic and acetylcholinergic agents, as well as deanol and placebo. Responses formed two subgroups, with some patients improving with deanol and others worsening or showing no response.
Deanol in the treatment of hyperkinetic children.
The paper is an RCT studying the use of deanol in the treatment of hyperkinetic children. No abstract is available to provide further details.
A pilot evaluation of deanol in the treat- ment of anxiety.
Pilot evaluation of deanol in the treatment of anxiety, classified as a randomized controlled trial.
Deanol (paxanol) in anxiety. (A contribution to the methodology of cross-over studies).
The paper appears to be a randomized controlled trial studying the effects of Deanol (paxanol) in anxiety, contributing to the methodology of cross-over studies.
Approach to a combined pharmacologic therapy of childhood hyperkinesis.
Clinical trial in 30 children aged 5-10 years using 2-dimethylaminoethanol in association with a magnesium salt of dipropylacetic acid for the management of childhood hyperkinesis.
Cholinergic influences in tardive dyskinesia.
Placebo-controlled double-blind study of physostigmine, choline, and deanol in 12 patients with tardive dyskinesia. Physostigmine and choline showed a positive therapeutic effect, though physostigmine's effect may be due to sedation. Deanol was not effective.
Mood alterations during deanol therapy.
Study of 38 patients taking high doses of deanol, an acetylcholine precursor. Eight patients experienced mood changes: five became depressed and three became hypomanic. A predisposition is suggested as seven of these eight had histories of affective symptoms.